Multiple sclerosis (MS) is a lifelong disease with a high risk of permanent disability. Current information on the long-term efficacy and safety of treatment is therefore absolutely essential for the optimal choice of therapeutic agent – in this case, ocrelizumab.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
